Press Releases October 5, 2026 06:30 AM

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

Fortrea announces Q3 2026 earnings release date and conference call details

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
FTRE

Fortrea, a Nasdaq-listed global contract research organization, announced it will release its third quarter 2026 financial results on October 29, 2026, before market open, followed by a conference call at 8:00 a.m. ET to discuss results. The company provides clinical development solutions for biopharmaceutical and medical device sectors worldwide.

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call
FTRE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Fortrea is set to announce Q3 2026 financial results on October 29, 2026.
  • A conference call will be held to discuss the results, with registration required for participation.
  • Fortrea operates globally in clinical development services including clinical trials management and pharmacology across over 20 therapeutic areas.

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.

To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call.

The live webcast can be accessed at investors.fortrea.com. A replay will be available in the Events and Presentations section of the site following the conclusion of the call.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts:

Tracy Krumme (Investors) – 984-385-6707, [email protected]
Sue Zaranek (Media) – 919-943-5422, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]


Risks

  • The announcement does not provide specific financial guidance, adding uncertainty regarding performance.
  • The clinical research sector faces risks from regulatory changes impacting trial timelines and costs.
  • Dependence on biopharmaceutical and medical device industry spending patterns creates exposure to sector-specific risks.

More from Press Releases

Gilat Awarded $28 Million Contract to Expand Connectivity in Peru Oct 5, 2026 Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders Oct 5, 2026 DV Launches Attribution Measurement and Advances Brand Suitability for ChatGPT Ads Oct 5, 2026 VisionWave Outlines Development of Autonomous Defense Ecosystem Across Tactical UAV and Counter-UAS Applications Oct 5, 2026 BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth Oct 5, 2026